The stock of Relay Therapeutics Inc. (NASDAQ:RLAY) increased by $0.36 on Friday to finish at $10.27, up 3.63 percent. The last five days have seen an average of 830,900 shares of common stock traded. 9 times new highs were reached in the current year, with a fall of -$4.67. The average number of shares traded over the last 20 days was 838,685, while the average volume over the last 50 days totaled 1,045,078.
RLAY stock dropped -12.22% since last month. On 08/25/23, the company’s shares reached a one-month low of $9.83. The stock touched a high of $33.06 on 02/02/23, after rallying from a low of $9.67 in 52 weeks. The price of RLAY stock has declined by -31.26% or -$4.67 this year, reaching a new high 9 times. Still, the stock price is down -68.94% from the 52-week high.
Insider Transactions
RLAY stock investors should be aware that Relay Therapeutics Inc. (RLAY) stock had its last reported insider trading activity 31 days ago on Jul 28. On Jul 28, President, R&D Bergstrom Donald A sold 2,683 shares at $11.80 each. This transaction resulted in the insider making $31,659. On Jul 28, Catinazzo Thomas sold 1,693 shares at a price of US$11.80. After the transaction, the insider now owns 146,136 shares. Chief Legal Officer Adams Brian had earlier sold 1,628 shares on Jul 28 for $11.80 a share. The transaction was completed for $19,210.
Valuation Metrics
Beta for the stock is 1.41. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1344.80, the price-to-book (PB) ratio of 1.54.
Financial Health
For the recent quarter, Relay Therapeutics Inc.’s quick ratio was 12.40, while its current ratio was 12.40, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $300.66 million and revenue of $1.38 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RLAY’s return on assets (ROA) during the last 12 months has been -32.30%. There was a -31.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -37.80%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.12 million, while revenues fell by -208.33% to $0.23 million. EBITDA was -$106.92 million for the quarter. At the end of Relay Therapeutics Inc.’s most recent quarter, its liabilities totaled 151.9 million, while its total debt was $55.71 million. Equity owned by shareholders amounts to $122.13 million.
Technical Picture
Here’s a quick look at Relay Therapeutics Inc.’s (RLAY) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 40.46%, suggesting the stock is Neutral, with a 51.41% historical volatility rate.
The stochastic %K and %D were 15.00% and 17.43% respectively, while the average true range (ATR) was 0.63. Based on the 14-day stochastic reading of 18.60%, the RSI (14) reading is 41.32%. On the 9-day MACD Oscillator, the stock is at -0.17, and the 14-day reading is at -0.37.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Relay Therapeutics Inc. (NASDAQ: RLAY) to a Hold. Prior to this, analysts firm rated the stock as an Underperform. Analysts have assigned Relay Therapeutics Inc. (RLAY) an Buy rating. RLAY is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 12 others recommend it as a buy.
What is RLAY’s price target for the next 12 months?
The current consensus forecast for the stock is between $15.00 and $38.00, with a median target price of $29.00. In analyzing these forecasts, the average price target given by analysts for Relay Therapeutics Inc. (RLAY) is $27.42.
